Abstract
Adenosine deaminase (ADA) deficiency is usually associated with severe combined immunodeficiency (SCID) and results in clinical, immunological and biochemical abnormalities. Biochemical abnormalities are characterized by accumulation of purine metabolites; adenosine, deoxyadenosine, dADP and dATP in biological fluids and cells,1,2. Untreated this disease is usually fatal during the first few months of life. The therapy of choice is bone-marrow transplantation from histocompatible donors3. Unfortunately in most instances, HLA-identical donors are not available. Thus others therapeutic approaches including gene therapy have to be considered. Enzyme replacement therapy in the form of repeated red cell transfusions has been of clinical benefit in some children but the response is often unsustained4. Recently, a new enzyme replacement therapy, polyethylene glycol-modified bovine ADA has been tested in some children with ADA deficiency and SCID5.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G. Morgan, G. Levinsky, K. Hugh-Jones, L.D. Fairbanks, G.S. Morris, H.A. Simmonds. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin. Exp. Immunol. 70: 491 (1987).
N.A. Kredrich, M.S. Hershfield. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: “The Metabolic basis of Inherited Disease”, (Edition McGraw-Hill, New-York (1989).
R.M. Blaese, D.B. Kohn, R.C. Moen. The treatment of adenosine deaminase deficiency. Immunol. Today 8: 296 (1987).
R. Hirchhorn. Inherited enzyme deficiencies and immunodeficiency: adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiencies. Clin. Immunol. Immunopathol. 40: 157 (1986).
M.S. Hershfield, R.H. Buckley, M.L. Greenberg, A.L. Melton, R. Schiff, C. Hatem, J. Kurtzberg, M.L. Marken, R.H. Kobayashi, A.L. Kobayashi, A. Abuchowski. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl.J. Med. 316: 589 (1987).
R. Boulieu, C. Bory, C. Gonnet. High performance liquid Chromatographic method for the analysis of purine and pyrimidine bases, ribonucleosides and deoxyribonucleosides in biological fluids. J. Chromatogr. 339: 380 (1985).
R. Boulieu, C. Bory, C. Gonnet. Liquid Chromatographic measurement of purine nucleotides in blood cells. Clin. Chem. 31: 727 (1985).
C. Bory, R. Boulieu, G. Souillet, C. Chantin, M.O. Rolland, M. Mathieu, M.S. Hershfield. Comparison of red cell transfusion and polyethylene glycol-modified adenosine deaminase therapy in an adenosine deaminase-deficient child: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool. Pediatr. Res. 28: 127 (1990).
R. Boulieu, C. Bory, G. Souillet. Purine metabolism in a bone marrow transplanted adenosine deaminase deficient patient. Clin. Chim. Acta 178: 349 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bory, C., Boulieu, R., Souillet, G., Chantin, C., Guibaud, P., Hershfield, M.S. (1991). Effect of Polyethylene Glycol-Modified Adenosine Deaminase (PEG-ADA) Therapy in Two ADA-Deficient Children: Measurement of Erythrocyte Deoxyadenosine Triphosphate as a Useful Tool. In: Harkness, R.A., Elion, G.B., Zöllner, N. (eds) Purine and Pyrimidine Metabolism in Man VII. Advances in Experimental Medicine and Biology, vol 309A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2638-8_39
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2638-8_39
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2640-1
Online ISBN: 978-1-4899-2638-8
eBook Packages: Springer Book Archive